Top Page
China NT Pharma Group Co., Ltd.
(1011)
China NT Pharma Group Co., Ltd. (1011) vs. iShares MSCI Hong Kong ETF (EWH)
China NT Pharma Group Co., Ltd. Business Overview & Revenue Model
China NT Pharma Group Co., Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.66M | 37.96M | 7.37M | 207.09M | 226.70M | 221.73M |
| Gross Profit | 9.57M | 5.26M | 7.37M | 125.29M | 145.46M | 134.90M |
| EBITDA | -7.35M | -8.65M | 1.33M | 10.39M | -17.78M | -52.76M |
| Net Income | -70.92M | -53.36M | -143.59M | -66.41M | -149.54M | -357.60M |
Balance Sheet | ||||||
| Total Assets | 344.41M | 334.07M | 329.12M | 1.01B | 955.36M | 1.30B |
| Cash, Cash Equivalents and Short-Term Investments | 4.63M | 9.62M | 1.52M | 5.93M | 9.44M | 7.69M |
| Total Debt | 316.72M | 375.95M | 344.94M | 826.45M | 832.11M | 851.46M |
| Total Liabilities | 621.29M | 733.18M | 668.69M | 1.25B | 1.17B | 1.27B |
| Stockholders Equity | -276.88M | -399.11M | -339.56M | -241.66M | -211.38M | 16.28M |
Cash Flow | ||||||
| Free Cash Flow | -22.61M | -9.24M | 37.58M | 31.72M | -135.42M | 2.36M |
| Operating Cash Flow | -22.56M | -9.07M | 50.48M | 36.21M | -134.78M | 26.20M |
| Investing Cash Flow | -55.00K | -189.00K | -22.14M | 4.53M | 257.81M | 595.60M |
| Financing Cash Flow | 23.02M | 12.65M | -28.97M | -46.68M | -124.80M | -624.25M |
China NT Pharma Group Co., Ltd. Technical Analysis
China NT Pharma Group Co., Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$281.90M | 42.05 | 0.72% | 3.51% | -5.98% | -81.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$536.71M | -2.85 | -40.38% | ― | -43.46% | -96.48% | |
48 Neutral | HK$525.91M | -3.10 | ― | ― | ― | ― | |
48 Neutral | HK$201.03M | -38.24 | -8.71% | ― | 2.54% | 33.33% | |
46 Neutral | HK$405.04M | -29.27 | -1.16% | 7.50% | 59.60% | -351.02% | |
44 Neutral | HK$217.15M | -3.23 | -13.08% | ― | -19.28% | -42.27% |
China NT Pharma Group Co., Ltd. Corporate Events
China NT Pharma has outlined progress on its transition to an AI-driven, light-asset healthcare model and measures to bolster liquidity, following a previously disclosed going-concern disclaimer in its 2024 annual report. The group is moving to complete the acquisition of three target companies that effectively give it control of about 58.11% of Zhejiang Kangyuan Medical Equipment, allowing it to integrate core AI bone health diagnostic products such as an AI X-ray bone density system and portable AI X-ray devices, together with associated patents and software, to deepen its presence in AI-based bone health testing and robotics. Its orthopedic drug agency and orthopedic health product businesses are delivering stable revenue in the treatment segment, while partnerships formed in 2025 with a Chinese state-owned enterprise and a health management company to run a smart health management center and digital health services are expected to provide additional steady income streams from 2026. To address liquidity and going-concern concerns, the group has secured extensions or waivers on most loans for the next 12 months, is negotiating further debt term adjustments, and has obtained commitments from major shareholders for continued financial support through loans, underpinning its strategic transformation and near-term debt service capability.
The most recent analyst rating on (HK:1011) stock is a Hold with a HK$0.81 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.
China NT Pharma Group has secured shareholder approval at its extraordinary general meeting to issue and allot up to 274,751,679 new shares at HK$0.45 each as consideration for acquiring 100% of the issued shares of Junbinxiongdi Limited, Yuehua Limited and Zhong He Qun Lian Limited. This transaction will give the company effective control over approximately 58.11% of Zhejiang Kangyuan Medical Device Co., Ltd., signalling a strategic expansion into the medical device business and potentially strengthening its position in China’s healthcare market through increased vertical integration and diversification of revenue streams.
The most recent analyst rating on (HK:1011) stock is a Hold with a HK$0.92 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.
China NT Pharma Group has convened an extraordinary general meeting for 15 January 2026 in Hong Kong to seek shareholder approval for the acquisition of 100% of the issued shares in three target companies—Junbinxiongdi Limited, Yuehua Limited and Zhong He Qun Lian Limited—under a sale and purchase agreement signed on 28 April 2025. The board is asking shareholders to ratify the agreement, approve the issuance and allotment of up to 274,751,679 new consideration shares at HK$0.45 each under a specific mandate to pay the sellers, and authorise directors to implement and, if necessary, amend the transaction once the Stock Exchange grants listing approval for the new shares, a move that would expand the group’s asset base while diluting existing holdings but potentially strengthening its strategic positioning in the market.
The most recent analyst rating on (HK:1011) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.
China NT Pharma Group has signed a supplemental agreement to revise the payment terms of its previously announced acquisition of 100% of the issued shares in certain target companies, which will be settled through the issuance of consideration shares under a specific mandate. The consideration of RMB116.2 million will now be fully satisfied by allotting and issuing consideration shares to the sellers on a pro rata basis within 30 days after both the successful registration and granting of a medical device registration certificate for the company’s Portable Digital X-Ray Diagnostic Robot System in Zhejiang Province and completion of the deal, while the long stop date for closing has been extended to 28 April 2026, aligning the timetable and conditions of the transaction more closely with regulatory approval milestones and potentially affecting the pace of its expansion into the medical device segment.
The most recent analyst rating on (HK:1011) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.
China NT Pharma Group Co., Ltd. has announced significant changes in its corporate governance structure with the appointment of Ms. Li Yifang as the company secretary, authorized representative, and agent for the acceptance of service of process and notices in Hong Kong, effective from November 25, 2025. This strategic appointment of Ms. Li, who brings extensive experience in regulatory compliance and corporate governance, is expected to enhance the company’s operational efficiency and strengthen its compliance framework, potentially impacting its positioning in the industry.
The most recent analyst rating on (HK:1011) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.
China NT Pharma Group Co., Ltd. is transforming into a high-tech medical enterprise driven by artificial intelligence to adapt to market changes and capitalize on opportunities in China’s growing orthopedic market. The company aims to build a comprehensive healthcare ecosystem focusing on testing, treatment, and rehabilitation in bone health, leveraging AI technology and national orthopedic initiatives to ensure continued business development and provide end-to-end solutions.
The most recent analyst rating on (HK:1011) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.